Breakthrough Alzheimer's Therapy Lormalzi Aims to Transform Early Diagnosis in India

Eli Lilly's Lormalzi, an Alzheimer's therapy designed to slow disease progression, has been launched in India. Targeting early-stage patients, it requires timely diagnosis and biomarker testing. Despite its high cost and side effects, this treatment marks a paradigm shift from symptom management to disease-modifying strategies in Alzheimer's care.

In a groundbreaking development for Alzheimer's treatment in India, Eli Lilly has introduced Lormalzi (donanemab), a therapy aimed at slowing the progression of the neurodegenerative disorder in its early stages. Distinguished from traditional therapies that manage symptoms, Lormalzi targets amyloid-beta plaques, thus addressing the underlying brain alterations.

Dr Manjari Tripathi from AIIMS emphasizes early diagnosis and the importance of biomarker detection for effective treatment. Despite concerns over cost and potential side effects, such as brain swelling, experts believe Lormalzi signals a new era in Alzheimer's treatment, focusing on disease modification rather than symptom management.

With a cost potentially approaching Rs 60 lakh over 18 months, accessibility remains a barrier. However, Dr Suri from Indraprastha Apollo Hospital notes that this therapy may preserve memory and cognitive function when administered in the initial stages of cognitive decline, marking a significant advancement for future Alzheimer's care in India.